Nöroendokrin Tümörlerde Prognostik Faktörler Tek Merkez Deneyimi

Amaç: Nöroendokrin tümörler nadir görülmekle birlikte yerleşim yeri, biyolojik davranışları ve klinik seyir açısından çeşitlilik gösterebilen heterojen bir tümör grubudur. Çalışmamızda merkezimizde takip edilen nöroendokrin tümör tanısı almış olan olguların demografik özelliklerinin ve prognostik faktörlerinin retrospektif olarak tespit edilmesi amaçlandı. Gereç ve Yöntem: Ocak 1994 ve Eylül 2015 tarihleri arasında İstanbul Üniversitesi Cerrahpaşa Tıp Fakültesi Hastanesi Medikal Onkoloji polikliniğinde nöroendokrin tümör tanısı almış 110 hasta alındı. Hastaların demografik verileri ve prognostik belirteçler hasta dosyalarından retrospektif olarak elde edildi. Bulgular: Hastaların yaş ortalaması 55±13 ve %57'si (n =63) erkekti. Primer tümör bölgesi olarak en sık pankreas (%30) yerleşimliydi. Olguların %70’i (n =77) tanı anında metastatik evredeydi ve en sık metastaz yeri karaciğer olarak tespit edildi. Olguların %13’ünde ise primer odak bulunamamıştır. Hastalarda görülen ilk semptom en sık karın ağrısı olurken (%51), asemptomatik olguların oranı %12 idi. Metastatik hastalıkla tümör belirteçleri arasında sadece karsinoembriyonik antijen düzeyleri arasında anlamlı farklılık saptanırken (p =0.02), diferansiasyon derecesiyle ise sadece nöron spesifik enolaz düzeyleri ilişkili bulunmuştur (p =0.008). Mortalite ileri yaş (p

Prognostic Factors in Neuroendocrine Tumors Single Center Experience

Objective: Neuroendocrine tumors are rare but constitute a heterogeneous group of tumors in terms of localization and clinical prognosis. The aim of this study was to determine the demographic charecteristics of patients with neuroendocrine tumors and prognostic factors in the clinical course of the disease in a single reference center. Material and Method: Patients with a diagnosis of neuroendocrine tumors referred to Istanbul University Cerrahpasa Medical Faculty Medical Oncology department between January 1994 and September 2015 were included in the study. The files of 110 patients were retrospectively analysed. Results: The mean age of the patients was 55±13 years and 57% were male. The most common site of origin was pancreas (30%). Seventy percent (n =77) of patients were metastatic at diagnosis and liver was the most frequent site of metastasis. While the most common symptom firstly reported by the patients was abdominal pain (51%), the rate of asymptomatic cases was 12%. When metastatic disease and tumor markers were compared, there was a significant difference among carcinoembryonic antigen levels (p =0.02). The degree of differentiation associated with neuron specific enolase levels (p =0.008). Mortality was associated with older age (p

PDF

___

1. Spigel DR, Hainsworth JD and Greco FA. Neuroendocrine carcinoma of unknown primary site. Semin Oncol 2009; 36: 52-9.
2. Guilmette JM and Nosé V. Neoplasms of the neuroendocrine pancreas: An update in the classification, definition, and molecular genetic advances. Adv Anat Pathol 2019; 26: 13-30.
3. Basuroy R, Bouvier C, Ramage JK, Sissons M, Srirajaskanthan R. Delays and routes to diagnosis of neuroendocrine tumours. BMC Cancer 2018; 18: 1122.
4. Dasari A, Shen C, Halperin D et al. Trends in the ıncidence, prevalence, and survival outcomes in patients with neuroendocrine tumors in the united states. JAMA Oncol 2017; 3: 1335-42.
5. Yao JC, Hassan M, Phan A et al. One hundred years after "carcinoid": epidemiology of and prognostic factors for neuroendocrine tumors in 35,825 cases in the United States. J Clin Oncol 2008; 26: 3063-72.
6. Fan JH, Zhang YQ, Shi SS et al. A nation-wide retrospective epidemiological study of gastroenteropancreatic neuroendocrine neoplasms in china. Oncotarget 2017; 8: 71699-708.
7. Tsai HJ, Wu CC, Tsai CR, Lin SF, Chen LT, Chang JS. The epidemiology of neuroendocrine tumors in Taiwan: a nation-wide cancer registrybased study. PLoS One 2013; 8: e62487.
8. Altieri B, Barrea L, Modica R et al. Nutrition and neuroendocrine tumors: An update of the literature. Rev Endocr Metab Disord 2018; 19: 159-67.
9. Pavel M, Toole DO, Costa F et al. ENETS Consensus Guidelines Update For The Management Of Distant Metastatic Disease Of Intestinal, Pancreatic, Bronchial Neuroendocrine Neoplasms (NEN) and NEN of unknown primary site. Neuroendocrinology 2016; 103: 172-85.
10. Polish A, Vergo M and Agulnik M. Management of neuroendocrine tumors of unknown origin. J Natl Compr Canc Netw 2011; 9: 1397-402.
11. Coriat R, Walter T, Terris B, Couvelard A and Ruszniewski P. Gastroenteropancreatic Well- Differentiated grade 3 neuroendocrine tumors: Review and position statement. Oncologist 2016; 21: 1191-9.
12. Lyubimova NV, Churikova TK and Kushlinskii NE. Chromogranin as a biochemical marker of neuroendocrine tumors. Bull Exp Biol Med 2016; 160: 702-4.
13. Viola D and Elisei R. Management of medullary thyroid cancer. Endocrinol Metab Clin North Am 2019; 48: 285-301.
14. Fukuchi N, Ebisui C, Minoji T et al. A case of a duodenal GIST observed as a non-functional pancreatic neuroendocrine tumor. Gan To Kagaku Ryoho 2019; 46: 589-91.
15. Zhuge X, Guo C, Chen Y et al. The Levels of tumor markers in pancreatic neuroendocrine carcinoma and their values in differentiation between pancreatic neuroendocrine carcinoma and pancreatic ductal adenocarcinoma. Pancreas 2018; 47: 1290-5.
16. Lv Y, Han X, Zhang C et al. Combined test of serum CgA and NSE improved the power of prognosis prediction of NF-pNETs. Endocr Connect 2018; 7: 169-78.
17. Gluckman CR and Metz DC. Gastric Neuroendocrine tumors (Carcinoids). Curr Gastroenterol Rep 2019; 21: 13.
18. Scott AT and Howe JR. Evaluation and Management of neuroendocrine tumors of the pancreas. Surg Clin North Am 2019; 99: 793-814.
19. Cives M and Strosberg JR. Gastroenteropancreatic neuroendocrine tumors. CA Cancer J Clin 2018; 68: 471-87.
20. Zandee WT, Kamp K, Adrichem RC, Feelders A and Herder WW. Effect of hormone secretory syndromes on neuroendocrine tumor prognosis. Endocr Related Cancer 2017; 24: 261-74.
21. Santos AP, Santos AC, Castro C et al. Visceral obesity and metabolic syndrome are associated with well-differentiated gastroenteropancreatic neuroendocrine tumors. Cancers 2018; 10: 293
22. Bosman FT, Carneiro F, Hruban RH et al. Neuroendocrine tumors of the GI tract WHO classification of tumors of digestive system. Lyon: WHO Press 2010.